Contrast agents have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential drivers in the widespread use of contrast agents in the future.
The global contrast media market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global contrast media market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.
The global contrast media market, though fairly mature at present (2012), still shows potential to grow over the next five years. It is propelled by the increasing demand for diagnostic imaging and image guided surgical procedures, technological advances in diagnostic imaging and the ever-increasing incidence rates of cancer and cardiac disorders. However, a few pivotal factors affecting the growth of this market are major economies of the world undergoing healthcare reforms, thereby affecting contrast media sales and the economic slowdown restricting the overall growth of this market.
The U.S. represents the largest contrast media market worldwide, followed by Europe and Japan. However, the economic slowdown has augmented opportunities for emerging markets like India and China to strengthen their position in the global arena. Advances in medical technology coupled with huge foreign investments from developed nations, allows these emerging markets to compete with global market leaders in this segment. Investment firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe, since the U.S. is on the brink of embracing healthcare reforms and major economies in Europe are still recovering from huge financial deficits.
The global marketplace is highly competitive, with several small players specific to a particular geography challenging major ones. Owing to the recession and the emerging opportunities in developing countries, many small companies have similar product offerings at competitive prices. Some of the major players profiled in this report are GE Healthcare (U.K.), Bracco Diagnostic, Inc. (Italy), Bayer Healthcare Pharmaceuticals (Germany), Covidien (Ireland) and Guerbet Group (France).
The scope of the report spans the global contrast media market which comprises:
Global Contrast Media Market, by Product
Barium-based contrast media
Iodinated contrast media
Low-osmolar contrast media (LOCM)
High-osmolar contrast media (HOCM)
Gadolinium-based contrast media
Global Contrast Media Market, by Route of Administration
Oral
Injection
Intravenous (I.V.)
Intra-arterial (I.A.)
Rectal
Urethral
Global Contrast Media Market, by Medical Procedure
X-ray
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Ultrasound
Catheterization laboratory (cath lab)
Global Contrast Media Market, by Indication
Cardiovascular disorders
Neurological disorders
Gastrointestinal disorders
Respiratory diseases
Musculoskeletal anomalies
Nephrological disorders
Oncology (tumor detection)
Global Contrast Media Market, by Application
Radiology
Interventional radiology
Interventional cardiology
Contrast Media Market, by Geography
North America
U.S.
Canada
Europe
United Kingdom (U.K.)
Germany
France
Italy
Spain
Scandinavian countries (Sweden, Denmark, Finland, and Norway)
Rest of Europe
Asia-Pacific (APAC)
Japan
China
India
Rest of Asia-Pacific
Rest of the world (RoW)
Latin America
Middle East & Africa
Russia
Each section of the report offers market data for the various market segments and geographies. It also provides in-depth information on market trends with respect to drivers, restraints, opportunities and technology trends.
Global Medical Imaging Industry
TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 KEY TAKE-AWAYS 21
1.2 REPORT DESCRIPTION 22
1.3 MARKETS COVERED 23
1.4 STAKEHOLDERS 26
1.5 RESEARCH METHODOLOGY 27
1.5.1 MARKET SIZE 27
1.5.2 MARKET SHARE 27
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 27
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 28
2 EXECUTIVE SUMMARY 29
3 MARKET OVERVIEW 33
3.1 INTRODUCTION 34
3.2 MARKET SEGMENTATION 35
3.3 MARKET DYNAMICS 36
3.3.1 DRIVERS 37
3.3.1.1 Increasing demand for diagnostic & image guided procedures influences contrast media sales 37
3.3.1.2 Technological advancements to spur the contrast media market 37
3.3.1.3 Increasing incidence & mortality of cancer & cardiac diseases to boost growth of contrast media 38
3.3.1.4 Growth of medical imaging technology in emerging markets 38
3.3.2 RESTRAINTS 39
3.3.2.1 Major economies undergoing healthcare reforms to affect the sales on contrast media 39
3.3.2.2 Economic slowdown to inhibit growth 40
3.3.3 OPPORTUNITIES 41
3.3.3.1 Growing investment potential in immature emerging markets 41
3.3.3.2 Advent of novel contrast agents combining properties of contrast media & radiopharmaceuticals 41
3.3.4 BURNING ISSUE - TOXICITY 42
3.3.4.1 Nephrogenic systemic fibrosis (NSF) 42
3.3.4.2 Contrast-induced nephrotoxicity (CIN) 43
3.3.5 TECHNOLOGY TRENDS 44
3.3.5.1 N1177 – A revolutionary macrophage labeling agent 44
3.3.5.2 SPAGO Pix – Accurate visualization of tumors with MRI 46
3.3.5.3 CMC-001 – Focused on liver MRI 46
3.4 MARKET SHARE ANALYSIS 47
4 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT 50
4.1 INTRODUCTION 51
4.2 BARIUM-BASED CONTRAST MEDIA 55
4.2.1 TECHNICAL OVERVIEW 55
4.2.2 MARKET DYNAMICS 56
4.2.3 MARKET ANALYSIS 56
4.3 IODINATED CONTRAST MEDIA 58
4.3.1 TECHNICAL OVERVIEW 58
4.3.2 MARKET DYNAMICS 58
4.3.3 MARKET ANALYSIS 59
4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR 61
4.3.4.1 Low-osmolar contrast media (LOCM) 61
4.3.4.1.1 Technical overview 61
4.3.4.1.2 Market analysis 63
4.3.4.2 High-osmolar contrast media (HOCM) 64
4.3.4.2.1 Technical overview 64
4.3.4.2.2 Market analysis 65
4.4 GADOLINIUM-BASED CONTRAST MEDIA 66
4.4.1 TECHNICAL OVERVIEW 66
4.4.2 MARKET DYNAMICS 67
4.4.3 MARKET ANALYSIS 67
5 GLOBAL CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 69
5.1 INTRODUCTION 70
5.2 ORAL CONTRAST MEDIA 73
5.2.1 TECHNICAL OVERVIEW 73
5.2.2 MARKET DYNAMICS 73
5.2.3 MARKET ANALYSIS 74
5.3 INJECTABLE CONTRAST MEDIA 75
5.3.1 TECHNICAL OVERVIEW 75
5.3.2 MARKET DYNAMICS 76
5.3.3 MARKET ANALYSIS 77
5.3.4 INJECTABLE CONTRAST MEDIA – TYPES 78
5.3.4.1 Intravenous (IV) 78
5.3.4.2 Intra-Arterial (IA) 79
5.4 RECTAL CONTRAST MEDIA 81
5.4.1 TECHNICAL OVERVIEW 81
5.4.2 MARKET DYNAMICS 81
5.4.3 MARKET ANALYSIS 82
5.5 URETHRAL CONTRAST MEDIA 83
5.5.1 TECHNICAL OVERVIEW 83
5.5.2 MARKET DYNAMICS 83
5.5.3 MARKET ANALYSIS 84
6 GLOBAL CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE 86
6.1 INTRODUCTION 87
6.2 X-RAY 89
6.2.1 TECHNICAL OVERVIEW 89
6.2.2 MARKET DYNAMICS 90
6.2.3 MARKET ANALYSIS 91
6.3 COMPUTED TOMOGRAPHY (CT) 92
6.3.1 TECHNICAL OVERVIEW 92
6.3.2 MARKET DYNAMICS 93
6.3.3 MARKET ANALYSIS 93
6.4 MAGNETIC RESONANCE IMAGING (MRI) 94
6.4.1 TECHNICAL OVERVIEW 94
6.4.2 MARKET DYNAMICS 95
6.4.3 MARKET ANALYSIS 96
6.5 ULTRASOUND 97
6.5.1 TECHNICAL OVERVIEW 97
6.5.2 MARKET DYNAMICS 97
6.5.3 MARKET ANALYSIS 98
6.6 CATHETERIZATION LABORATORY (CATH LAB) 99
6.6.1 TECHNICAL OVERVIEW 99
6.6.2 MARKET DYNAMICS 100
6.6.3 MARKET ANALYSIS 101
7 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION 102
7.1 INTRODUCTION 103
7.2 CARDIOVASCULAR DISORDERS 105
7.2.1 MARKET DYNAMICS 105
7.2.2 MARKET ANALYSIS 106
7.3 NEUROLOGICAL DISORDERS 107
7.3.1 MARKET DYNAMICS 107
7.3.2 MARKET ANALYSIS 107
7.4 RESPIRATORY DISEASES 109
7.4.1 MARKET DYNAMICS 109
7.4.2 MARKET ANALYSIS 109
7.5 GASTROINTESTINAL DISORDERS 111
7.5.1 MARKET DYNAMICS 111
7.5.2 MARKET ANALYSIS 111
7.6 ONCOLOGY 113
7.6.1 MARKET DYNAMICS 113
7.6.2 MARKET ANALYSIS 113
7.7 MUSCULOSKELETAL ANOMALIES 115
7.7.1 MARKET DYNAMICS 115
7.7.2 MARKET ANALYSIS 116
7.8 NEPHROLOGICAL DISORDERS 117
7.8.1 MARKET DYNAMICS 117
7.8.2 MARKET ANALYSIS 117
8 GLOBAL CONTRAST MEDIA MARKET, BY APPLICATION 119
8.1 INTRODUCTION 120
8.2 RADIOLOGY 123
8.2.1 TECHNICAL OVERVIEW 123
8.2.2 MARKET DYNAMICS 123
8.2.3 MARKET ANALYSIS 124
8.3 INTERVENTIONAL RADIOLOGY 126
8.3.1 TECHNICAL OVERVIEW 126
8.3.2 MARKET DYNAMICS 126
8.3.3 MARKET ANALYSIS 127
8.4 INTERVENTIONAL CARDIOLOGY 129
8.4.1 TECHNICAL OVERVIEW 129
8.4.2 MARKET DYNAMICS 130
8.4.3 MARKET ANALYSIS 130
9 GEOGRAPHIC ANALYSIS 132
9.1 INTRODUCTION 133
9.2 NORTH AMERICA 134
9.3 EUROPE 143
9.4 ASIA-PACIFIC 152
9.5 REST OF THE WORLD (ROW) 161
10 COMPETITIVE LANDSCAPE 169
10.1 INTRODUCTION 169
10.2 MERGERS & ACQUISITIONS 172
10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 174
10.4 NEW PRODUCT LAUNCH 178
10.5 EXPANSION 180
10.6 APPROVALS 182
10.7 OTHER DEVELOPMENTS 184
11 COMPANY PROFILES 187
11.1 AMAG PHARMACEUTICALS, INC. 195
11.2 BAYER HEALTHCARE PHARMACEUTICALS 199
11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A) 209
11.4 COVIDIEN 213
11.5 CMC CONTRAST AB 220
11.6 DAIICHI SANKYO CO., LTD. 222
11.7 GE HEALTHCARE 228
11.8 GENOVIS AB 235
11.9 GUERBET GROUP 240
11.10 LANTHEUS MEDICAL IMAGING, INC. 247
11.11 NANOPET PHARMA GMBH 254
11.12 NANOSCAN IMAGING, LLC 258
11.13 SANOCHEMIA PHARMAZEUTIKA AG 260
11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB) 267
11.15 SUBHRA PHARMA PRIVATE, LTD 271
11.16 TAEJOON PHARM CO., LTD. 274
11.17 TARGESON, INC. 278
11.18 UNIJULES LIFE SCIENCES, LTD. 283
LIST OF TABLES
TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,
2010 – 2017 ($MILLION) 30
TABLE 2 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 32
TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES 43
TABLE 4 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,
2010 - 2017 ($MILLION) 52
TABLE 5 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 53
TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION) 57
TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 60
TABLE 8 IODINATED CONTRAST MEDIA MARKET REVENUE, BY TYPE,
2010 - 2017 ($MILLION) 61
TABLE 9 IODINATED-LOCM CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 63
TABLE 10 IODINATED-HOCM CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65
TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 - 2017 ($MILLION) 68
TABLE 12 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 71
TABLE 13 ORAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 75
TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 77
TABLE 15 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,
2010 – 2017 ($MILLION) 78
TABLE 16 INTRAVENOUS INJECTABLE CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 79
TABLE 17 INTRA-ARTERIAL INJECTABLE CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 80
TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 82
TABLE 19 URETHRAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 85
TABLE 20 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 88
TABLE 21 X-RAY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 91
TABLE 22 CT CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 94
TABLE 23 MRI CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 96
TABLE 24 ULTRASOUND CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 98
TABLE 25 CATH LAB CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 101
TABLE 26 GLOBAL CONTRAST MEDIA MARKET, BY INDICATION,
2010 – 2017 ($MILLION) 104
TABLE 27 CARDIOVASCULAR DISEASES - CONTRAST MEDIA MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 106
TABLE 28 NEUROLOGICAL DISORDERS - CONTRAST MEDIA MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 108
TABLE 29 RESPIRATORY DISEASES - CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 110
TABLE 30 GASTROINTESTINAL DISORDERS - CONTRAST MEDIA MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 112
TABLE 31 ONCOLOGY - CONTRAST MEDIA MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 114
TABLE 32 MUSCULOSKELETAL ANOMALIES – CONTRAST MEDIA MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 116
TABLE 33 NEPHROLOGICAL DISORDERS - CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 118
TABLE 34 GLOBAL CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,
2010 – 2017 ($MILLION) 122
TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 125
TABLE 36 INTERVENTIONAL RADIOLOGY CONTRAST MEDIA MARKET REVENUE,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 128
TABLE 37 INTERVENTIONAL CARDIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 131
TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 133
TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 135
TABLE 40 NORTH AMERICA: CONTRAST MEDIA MARKET, BY PRODUCT,
2010 – 2017 ($MILLION) 136
TABLE 41 NORTH AMERICA: IODINATED CONTRAST MEDIA MARKET, BY TYPE, 2010 – 2017 ($MILLION) 137
TABLE 42 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 138
TABLE 43 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION,
2010 – 2017 ($MILLION) 139
TABLE 44 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 140
TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,
BY TYPE, 2010 – 2017 ($MILLION) 141
TABLE 46 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION) 142
TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 144
TABLE 48 EUROPE: CONTRAST MEDIA MARKET, BY PRODUCT,
2010 – 2017 ($MILLION) 145
TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,
2010 – 2017 ($MILLION) 146
TABLE 50 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 147
TABLE 51 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION,
2010 – 2017 ($MILLION) 148
TABLE 52 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 149
TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,
2010 – 2017 ($MILLION) 150
TABLE 54 EUROPE: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,
2010 – 2017 ($MILLION) 151
TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 153
TABLE 56 APAC: CONTRAST MEDIA MARKET, BY PRODUCT,
2010 – 2017 ($MILLION) 154
TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,
2010 – 2017 ($MILLION) 155
TABLE 58 APAC: CONTRAST MEDIA MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 156
TABLE 59 APAC: CONTRAST MEDIA MARKET, BY INDICATION,
2010 – 2017 ($MILLION) 157
TABLE 60 APAC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 158
TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,
2010 – 2017 ($MILLION) 159
TABLE 62 APAC: CONTRAST MEDIA MARKET, BY MEDICAL PROCEDURE,
2010 – 2017 ($MILLION) 160
TABLE 63 ROW: CONTRAST MEDIA MARKET REVENUE, BY REGION,
2010 – 2017 ($MILLION) 161
TABLE 64 ROW: CONTRAST MEDIA MARKET REVENUE, BY PRODUCT,
2010 – 2017 ($MILLION) 162
TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,
2010 – 2017 ($MILLION) 163
TABLE 66 ROW: CONTRAST MEDIA MARKET REVENUE, BY APPLICATION,
2010 – 2017 ($MILLION) 164
TABLE 67 ROW: CONTRAST MEDIA MARKET REVENUE, BY INDICATION,
2010 – 2017 ($MILLION) 165
TABLE 68 ROW: CONTRAST MEDIA MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 166
TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,
2010 – 2017 ($MILLION) 167
TABLE 70 ROW: CONTRAST MEDIA MARKET REVENUE, BY MEDICAL PROCEDURE,
2010 – 2017 ($MILLION) 168
TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012 172
TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012 174
TABLE 73 NEW PRODUCT LAUNCH, 2010 – 2012 178
TABLE 74 EXPANSION, 2010 – 2012 180
TABLE 75 APPROVALS, 2010 – 2012 182
TABLE 76 OTHER DEVELOPMENTS, 2010 – 2012 184
TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 196
TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 197
TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 – 2011 ($MILLION) 197
TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 200
TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,
BY SEGMENT, 2009 – 2011 ($MILLION) 201
TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,
BY GEOGRAPHY, 2009 – 2011 ($MILLION) 202
TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 – 2011 ($MILLION) 203
TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 203
TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 - 2011 ($MILLION) 204
TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 205
TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 – 2011 ($MILLION) 214
TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 – 2011 ($MILLION) 215
TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,
2009 – 2011 ($MILLION) 216
TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 217
TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,
2009 – 2011 ($BILLION) 223
TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 224
TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 229
TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,
2009 – 2011 ($BILLION) 229
TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 230
TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($THOU.S.ND) 236
TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($THOU.S.ND) 236
TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 241
TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 – 2012 ($MILLION) 242
TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 – 2012 ($MILLION) 243
TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 248
TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 248
TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 249
TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 261
TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2011 ($MILLION) 262
TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION) 263
TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($THOU.S.ND) 268
LIST OF FIGURES
FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 31
FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION 35
FIGURE 3 MARKET DYNAMICS 36
FIGURE 4 GLOBAL CONTRAST MEDIA MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2011 48
FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT 51
FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM) 62
FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM) 64
FIGURE 8 CONTRAST MEDIA MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION 70
FIGURE 9 CONTRAST MEDIA MARKET SEGMENTATION, BY MEDICAL PROCEDURE 87
FIGURE 10 CONTRAST MEDIA MARKET SEGMENTATION, BY INDICATION 103
FIGURE 11 CONTRAST MEDIA MARKET SEGMENTATION, BY APPLICATION 121
FIGURE 12 KEY GROWTH STRATEGIES, 2010 – 2012 169
FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 – 2012 170
FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,
2010 – 2012 171
